Zacks small cap research.

Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ...Zacks Small-Cap Research M. Marin 312-265 9211 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 August 30, 2022 BTCY: Health Monitoring Ecosystem is Expanding With New & Upcoming Products BCTY is …On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.MIRA Continues to Pursue New Pain Relief. 11/14/2023. By Brad Sorensen, CFA. NASDAQ:MIRA. READ THE FULL MIRA RESEARCH REPORT. MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it...

ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other serious illnesses.Investrade has good news to share - we are providing all customers FREE Snapshot research reports from Zacks Investment Research. There are reports on 4400 ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Zacks Rank N/A Obtaining Capital Zacks Small-Cap Research Sponsored – Impartial – Comprehensive 312 scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 February 14, 2023 John D. Vandermosten, CFA -265 9588 / [email protected] ESTIMATES Revenue Q1 Q2 Q3 Q4 YearThe following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...By David Bautz, PhD. NASDAQ:MDNA. READ THE FULL MDNA RESEARCH REPORT. Business Update. Update on ABILITY Trial. Medicenna Therapeutics Corp. (NASDAQ:MDNA) is currently conducting the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid …19 May 2013 ... Zacks is a hoax. Top rated stocks become low rated stock very quickly. Out of approximately 20 top pick I had two that made money and all ...Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believe

Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.

Nov 15, 2023 · The NELL-1 technology is the centerpiece of what Bone Biologics (NASDAQ:BBLG) is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness ...

Giles Haycock Managing Director (T) 312.265.9351 (M) 312.752.6718 (F) 312.265.9560 (E) [email protected] Twitter: @ZacksSmallCap Steven Ralston, CFA Director of ResearchZACKS SMALL/MID CAP ETF. The Zacks Small/Mid Cap ETF seeks to generate consistent and sustainable returns while minimizing the risk of capital …Oct 31, 2023 · $31.77 USD -0.10 (-0.31%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of Oct 31, 2023 * Annual for three... By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view.By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatments

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT First Quarter 2022 Results On May 16, 2022, Novan Inc. (NASDAQ: ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information …By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in …By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase …Image: Bigstock 5 Top-Ranked Small-Cap Stocks to Boost Your Portfolio in 2021 (revised) Nalak Das December 14, 2020 TITN HZO STRT Better trading starts …2 days ago · This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Zacks Rank N/A FY21 Results; IO Revenues Analysis Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 January 11, 2022 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Dec) (Mar) (Jun) (Sep) (Sep)

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …When it comes to fastening two objects together, cap head bolts and cap head screws are two popular options. They both have a similar appearance, but they differ in their application and usage. In this article, we’ll explore the difference ...

Oct 17, 2022 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT Uxin Limited (NASDAQ:UXIN) operates a leading e-commerce platform for buying and selling used cars in China. The company also has two physical locations where customers can view and purchase cars in person. The company has recently transitioned to an inventory-owning model which provides customers with a comprehensive transaction SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …TOL Quick Quote. TOL. 81.27. +9.45%. Compare funds in the Small-Cap-ETFs. Compare similar funds using our ETF Categories. Zacks Investment Research. Our Research, Your Success.The winner of a $100,000 lottery prize would have 25 percent, or $25,000, withheld for federal income taxes. In 34 states, the prize would also be subject to state income taxes ranging from 3.4 percent to 10.8 percent, according to Zacks In...'Who needs breadth when we have Nvidia's beat?': We've been here before, and I can tell you it lasts longer than it should. Let's look at charts and indicators, past and present....NVDA We're in that part of the cycle wh...David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...

By John Vandermosten, CFA. NASDAQ:RVPH. READ THE FULL RVPH RESEARCH REPORT. 2Q:23 Financial and Operational Results. On August 15, 2023, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:23 financial and operational results and filed its Form 10-Q with the SEC. Since our previous update in …

The estimate for 2022 is up $1.56 (44.8%) in the last 90 days. The 2023 estimate is up $1.34 (33.6%) during the same time period. The earnings beat in the last quarter of 91.5% is greater than the ...INX (OTC:INXDF) announced that Republic Group, described as “a global financial firm operating a digital merchant bank and a network of investment platforms,” is investing $5.25 million into the company in exchange for approximately 9.5% of outstanding shares. The deal, according to INX, values INX at approximately $50 million before the ...ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other …Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023. Operational and scientific highlights for 2Q:23 and to date include: Import license granted for Indonesia, Malaysia and South Africa – April 2023. Teijin license fee remitted – April 2023. Three patent issue notifications received – April 2023.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Oct 26, 2023 · By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. Most On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.ORMP: Data from NASH Phase 2 Study – Positive Takeaways . 11/21/2022. Download (opens in new window)Zacks Rank N/A Correlation Study Complete Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 23, 2022 312-265-9588 / [email protected] Revenue (In millions of USD) Q1 Q2 Q3 Q4 Year06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Wheel center caps are an important component of your vehicle’s overall aesthetic appeal. Not only do they enhance the appearance of your wheels, but they also protect the hub and lug nuts from dirt, debris, and damage.By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling …Zacks Equity Research November 23, 2023. CVX Quick Quote CVX ... Overall, they are usually a stable option, with less risk and more sure-fire cash flows than …Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising Estimates as Q2 Comes in Way Above Expectations and Company Turns a Profit Compared to its peers in the fintech space who trade at an average of 14.9 times Instagram:https://instagram. ytd stock market returns 2023icici bank in usatd pricevanguard high dividend yield etf dividend Nov 22, 2023 · Transitioning to SaaS model from 1-time hardware sales focus, while maintaining traditional business LogicMark, Inc. (NASDAQ:LGMK) is transitioning to a SaaS model from a 1-time hardware sales model, while maintaining its traditional business. LGMK expects new products and services to both diversify ... uber fees for driverstradezero review The estimate for 2022 is up $1.56 (44.8%) in the last 90 days. The 2023 estimate is up $1.34 (33.6%) during the same time period. The earnings beat in the last quarter of 91.5% is greater than the ...By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Fiscal Year 2022 Financial Results On December 28, 2022, CEL-SCI Corporation (NYSE:CVM) submitted its fiscal year 2022 Form 10-K with the SEC concurrent with a press release announcing fiscal year 2022 results. ... SUBSCRIBE TO ZACKS SMALL CAP … fivg stock SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …“Yes! Success!” “Yes! Success!” It wasn’t quite “Mr. Watson. Come Here. I need you.” but it could prove to be just as revolutionary: Researchers at the University of Washington have completed the first experiment demonstrating human brain-t...